Stay updated on Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has removed a citation for a study on Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer, which may affect the credibility and completeness of the information presented.
    Difference
    0.2%
    Check dated 2025-05-17T18:26:18.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-26T11:00:35.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has updated the trial details for HER2 Positive Breast Cancer, including the clarification that masking is only applied during the Double-blind phase, and the revision number has changed from v2.14.4 to v2.15.0. Additionally, the names of the study directors, Jorge Ramos and Corinna Palanca-Wessels, have been added.
    Difference
    32%
    Check dated 2025-04-19T04:12:05.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-04T20:04:20.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-03-27T14:44:48.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.6%
    Check dated 2025-02-26T20:01:17.000Z thumbnail image

Stay in the know with updates to Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.